Healthcare Services

HER2-Positive Breast Cancer Market: Future Trends and Growth Outlook

April 22, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Projected Increase In Market Value Of The HER2-Positive Breast Cancer Market During 2026–2030?

The her2-positive breast cancer market size has experienced strong growth in recent years. It is projected to expand from $10.93 billion in 2025 to $11.7 billion in 2026, progressing at a compound annual growth rate (CAGR) of 7.1%. The growth observed historically can be attributed to several factors, including the increasing identification of her2-positive cases, a broadening of targeted oncology drug approvals, the development of hospital oncology infrastructure, the accessibility of monoclonal antibody therapies, and an increase in clinical trial activity.

The her2-positive breast cancer market size is projected to experience strong growth in the coming years, with expectations to reach $15.23 billion in 2030 at a compound annual growth rate (CAGR) of 6.8%. The expansion during the forecast period can be attributed to the increasing adoption of next-generation her2 inhibitors, the broadening penetration of biosimilars, a growing demand for precision oncology treatments, rising investment in targeted cancer research, and an increasing focus on improving survival outcomes. Key trends anticipated in the forecast period include the increasing adoption of her2-targeted antibody therapies, a growing use of antibody-drug conjugates, the expansion of companion diagnostic testing, a rising focus on early-stage targeted treatment, and enhanced integration of combination therapy approaches.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/her2-positive-breast-cancer-global-market-report

Which Key Factors Are Driving The HER2-Positive Breast Cancer Market Growth?

The robust integration of immunotherapy is expected to drive the expansion of the HER2-positive breast cancer market moving forward. This medical treatment involves enhancing or modifying the immune system’s natural ability to combat diseases such as cancer, infections, and autoimmune disorders. The widespread use of immunotherapy is attributed to its capacity to boost the immune system’s ability to detect and eliminate cancer cells, leading to better efficacy and fewer side effects compared to conventional treatments. For HER2-positive breast cancer, immunotherapy works by strengthening the body’s immune system to recognize and attack HER2-overexpressing cancer cells, thereby improving treatment outcomes and reducing the risk of recurrence. For instance, in July 2023, according to the American Association for Cancer Research, a US-based organization, in 2023, the FDA had approved 11 immune checkpoint inhibitors (ICIs), with at least one ICI authorized for the treatment of 20 different cancer types and for any solid tumor exhibiting specific molecular characteristics. Therefore, the strong adoption of immunotherapy is fueling the growth of the HER2-positive breast cancer market.

How Is The HER2-Positive Breast Cancer Market Categorized Across Its Segment Groups?

The her2-positive breast cancer market covered in this report is segmented –

1) By Treatment Type: Targeted Therapy, Chemotherapy, Endocrine Therapy, Immunotherapy, Other Treatment Types

2) By Route Of Administration: Parenteral, Oral, Other Routes Of Administrations

3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

4) By End User: Hospitals, Homecare, Specialty Clinics, Other End User

Subsegments:

1) By Targeted Therapy: HER2 Inhibitors (Trastuzumab, Pertuzumab), Tyrosine Kinase Inhibitors (TKIs), Antibody-Drug Conjugates (ADC), Small Molecule Inhibitors

2) By Chemotherapy: Anthracycline-based Chemotherapy, Taxane-based Chemotherapy, Platinum-based Chemotherapy, Combination Chemotherapy Regimens

3) By Endocrine Therapy: Selective Estrogen Receptor Modulators (SERMs), Aromatase Inhibitors, Estrogen Receptor Antagonists, Estrogen Deprivation Therapy

4) By Immunotherapy: Immune Checkpoint Inhibitors (PD-1/PD-L1 Inhibitors), Monoclonal Antibodies for Immune Modulation

5) By Other Treatment Types: Radiation Therapy, Surgical Interventions (Mastectomy, Breast Conserving Surgery)

Which Trends Are Guiding The Direction Of The HER2-Positive Breast Cancer Market?

Leading companies operating in the HER2-positive breast cancer market are concentrating on creating innovative therapies, such as HER2-directed antibody-drug conjugates (ADCs), to streamline and improve the patient treatment process. HER2-directed antibody-drug conjugates (ADCs) function as targeted cancer therapies, linking an antibody specific to HER2 with a cytotoxic drug to deliver it directly to HER2-positive cancer cells for more effective treatment. For instance, in January 2024, AstraZeneca India Pharma Ltd., an India-based biopharmaceutical company, launched Trastuzumab deruxtecan. This innovative therapy was developed through a collaboration between AstraZeneca and Daiichi Sankyo. Trastuzumab deruxtecan is a HER2-directed antibody-drug conjugate (ADC), which ensures the direct delivery of a cytotoxic drug to HER2-positive cancer cells, thereby providing a more targeted and effective treatment for patients.

Which Firms Are Influencing Competition In The HER2-Positive Breast Cancer Market?

Major companies operating in the her2-positive breast cancer market are F. Hoffmann-La Roche AG, AstraZeneca plc, Novartis International AG, Pfizer Inc., Eli Lilly and Company, Merck & Co. Inc., Amgen Inc., Daiichi Sankyo Co. Ltd., Takeda Pharmaceutical Company Limited, Bristol Myers Squibb, Sanofi S.A., GlaxoSmithKline plc, Bayer AG, Seagen Inc., MacroGenics Inc., BioNTech SE, Incyte Corporation, Zymeworks Inc., Ambrx Biopharma Inc., Mersana Therapeutics Inc.

Get The Full HER2-Positive Breast Cancer Market Report:

https://www.thebusinessresearchcompany.com/report/her2-positive-breast-cancer-global-market-report

Which Geographic Region Dominates The HER2-Positive Breast Cancer Market?

North America was the largest region in the HER2- positive breast cancer market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the her2-positive breast cancer market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized HER2-Positive Breast Cancer Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/her2-positive-breast-cancer-global-market-report

Browse Through More Reports Similar to the Global HER2-Positive Breast Cancer Market 2026, By The Business Research Company

Metastatic Hr Her2 Breast Cancer Market Report 2026

https://www.thebusinessresearchcompany.com/report/metastatic-hr-her2-breast-cancer-global-market-report

Breast Cancer Diagnostics Market Report 2026

https://www.thebusinessresearchcompany.com/report/breast-cancer-diagnostics-global-market-report

Breast Cancer Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/breast-cancer-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795